Spinraza in Canada: The criteria will be expanded

Quebec/Canada

to include patients who: are pre-symptomatic with two or three copies of SMN2 gene;

or

have had disease duration of less than six months, two copies of the SMN2 gene, and symptom onset after the first week after birth and on or before seven months of age; or

are under the age of 18 with symptom onset after six months of age and who have never achieved the ability to walk independently.

Patients will be required to undergo ongoing assessment to monitor for improvement over time and must meet renewal criteria for continuation of treatment.

Cure SMA Canada Facebook
CureSMA Canada News

Publicerat av

Liz

Att acceptera vad som händer och låt trollen i ljuset, kanske du borde att tro mer på dig själv

4 reaktioner till “Spinraza in Canada: The criteria will be expanded”

  1. 👏Congratulations Canada, you are doing it right. Do not rule out adults, as other countries do. It is ethically just right, everywhere in the countries where Spinraza is used for all, one celebrates progress and the victory over death.🙂

  2. Effective August 26, 2019, the Government of New Brunswick has expanded access to SPINRAZA™ as part of the NB Drug Plans Formulary Update.

    Following criteria are met

    Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation,
    or compound heterozygous mutation; and
    – Patient is not requiring permanent invasive ventilation; and
    – Patient who:
    • is pre-symptomatic with genetic documentation of two or three copies of the survival motor
    neuron 2 (SMN2) gene, or
    • has had disease duration less than 6 months, two copies of the SMN2 gene, and symptom onset after the first week of birth and on or before 7 months of age, or
    • is under the age of 18 with symptom onset after 6 months of age.

    Browse SMA Canada

Kommentarer inaktiverade.